Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission
Authors:
- 22 November 2023
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (3) , 363-371
Abstract
We retrospectively analyzed 155 AML patients with DAT mutations at diagnosis who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at complete remission. Of the 155 AML patients with DAT mutations at diagnosis, 59 (38.1%) patients had persisting DAT mutations pretransplantation. Compared to patients with pretransplant DAT transitions, patients with persisting DAT mutation burden were shown to be older (p = 0.004), and fewer patients had TET2 mutations at diagnosis (p = 0.033). Patients with persistent DAT mutation burden had shorter overall survival (OS) (3-year OS: 59.3% vs. 83.0%, p < 0.001) and disease-free survival (DFS) (3-year DFS: 56.1% vs. 83.0%, p < 0.001) with a higher cumulative incidence of relapse (CIR) (24.6% vs. 17.4%, p = 0.002) than those with DAT transitions. Additionally, multivariate analysis confirmed that persisting DAT mutations were an independent adverse factor for relapse, OS, and DFS. Collectively, persisting DAT mutations prior to allo-HSCT at complete remission for AML correlated with negative outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (82020108003)
- National Natural Science Foundation of China (82070187)
- Suzhou Science Project (SKY2021104)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- the Gusu Health Talent Program of Suzhou (GSWS2022003)
This publication has 34 references indexed in Scilit:
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Persistence of DNMT3A mutations at long‐term remission in adult patients with AMLBritish Journal of Haematology, 2014
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Landscape of TET2 mutations in acute myeloid leukemiaLeukemia, 2011
- Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2011
- DNMT3AMutations in Acute Myeloid LeukemiaNew England Journal of Medicine, 2010
- ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaBritish Journal of Haematology, 2010
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974